ASTEPRO ALLERGY (Azelastine Hydrochloride) Patent Expiration, LOE Window & CMS Spending
ASTEPRO ALLERGY (Azelastine Hydrochloride) by Bayer: FDA Orange Book core substance LOE 2028-06-04, 6 AB generics, $0 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Bayer |
| FDA Application & Pathway | N213872 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | 2028-06-04 |
| Last Listed Patent or Exclusivity Date | 2028-06-04 |
| Orange Book Patents (*PED Extensions) | 2 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 6 |
| 2024 CMS Total Public Spend | $0 |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $0 |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Bayer across sibling Meru public-data platforms.
- Predicate Ledger FDA 510(k)Bayer FDA 510(k) & Recall Cohortdevices.meruai.co →
- Protocol Ledger NIH ClinicalTrials.govBayer Clinical Trials & Approvalstrials.meruai.co →
- ERISA Ledger DOL Form 5500Bayer 401(k) & Form 5500 Planerisa.meruai.co →
- Plume Ledger EPA TRI & RCRABayer U.S. TRI & RCRA Facilitieshazmat.meruai.co →